Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 4/20 | 0.52 |
| ▸ | TPO | P07202 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1958859 | 0.88 | PDE4A (0.59) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL1460898 | 0.86 | PDE4A (0.75) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL562472 | 0.85 | PDE4A (0.69) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL1373494 | 0.83 | PDE4A (0.74) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL1461123 | 0.82 | PDE4A (0.57) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL27745079 | 0.81 | PDE4A (0.52) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL1776521 | 0.79 | MPO (0.61) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL10180927 | 0.78 | MPO (0.60) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL1775931 | 0.76 | MPO (0.53) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL1776729 | 0.76 | MPO (0.53) | PDE4AADORA2APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943625-B2 | Myeloperoxidase inhibitors; neuroinflammatory disorders; COPD; 3-(2-Ethoxy-2-methylpropyl)-2-thioxanthine | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | claimed |
| US-20090131459-A1 | 2-Thioxanthine Derivatives Acting as MPO-Inhibitors | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | claimed |
| US-20080221133-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | claimed |
| US-20140199316-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | SACKSTEIN ROBERT (US) | 2014-07-17 | — | — | US | disclosed |
| US-8765126-B2 | Methods of treating complications and disorders associated with G-CSF administration | SACKSTEIN ROBERT (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130224217-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | SACKSTEIN ROBERT (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2012151576-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | SACKSTEIN ROBERT (US) | 2012-11-08 | — | — | WO | disclosed |
| US-7943625-B2 | Myeloperoxidase inhibitors; neuroinflammatory disorders; COPD; 3-(2-Ethoxy-2-methylpropyl)-2-thioxanthine | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20090131459-A1 | 2-Thioxanthine Derivatives Acting as MPO-Inhibitors | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| EP-2029598-A1 | 2-THIOXANTHINE DERIVATIVES ACTING AS MPO-INHIBITORS | Astra Zeneca AB (SE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080221133-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2007142576-A1 | 2-THIOXANTHINE DERIVATIVES ACTING AS MPO-INHIBITORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140199316-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | MPO, CSF3R, CSF1R | PDE4A 1525/4885ADORA2A 2145/4885PDE4B 1547/4885 |
| US-20090131459-A1 | 2-Thioxanthine Derivatives Acting as MPO-Inhibitors | MPO, SERPINB1, XDH | PDE4A 1129/4885ADORA2A 1540/4885PDE4B 1424/4885 |
| US-20130224217-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | MPO, CSF3R, CSF1R | PDE4A 1525/4885ADORA2A 2145/4885PDE4B 1547/4885 |
| US-20080221133-A1 | Compounds | C1R, C1S, AKR1C3 | PDE4A 3823/4885ADORA2A 3228/4885PDE4B 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.